Skip to main content

500 mg as bolus followed by an extended infusion of 1500 mg of meropenem every 8 h failed to achieve in one-third of the patients an optimal PK/PD against non-resistant strains of these organisms: is CRRT responsible for this situation?

We read with great interest the recent paper by Kothekar et al. who conclude that in patients with severe sepsis or septic shock, extended infusions (EI) of 1000 mg of meropenem over 3 h, administered every 8 h on the first and third days, provided adequate coverage against sensitive strains of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii [1]. However, this dosing regimen failed to achieve a fraction of time (fT) > 4 μg/mL > 40 for activity against non-resistant strains of these organisms in more than one-third of patients [1]. A bolus of 500 mg followed by EI of 1500 mg every 8 h was predicted to achieve this target in all patients [1]. The question is why was this the case in this study. We would like to comment. Though the study excluded at baseline patients with calculated creatinine clearance < 50 mL/min and those not expected to survive for 72 h, the cohort of patients included in the study had severe sepsis, with a mean SOFA score at day 1 of 7.35 ± 3.62 and 60% required inotropes. As such, we would expect a higher likelihood of acute kidney injury (AKI) and the need for renal replacement therapy (RRT) in this cohort. Nearly half of critically ill patients, especially those with septic shock, have or develop AKI and 20–25% need RRT within the first week of admission to intensive care [2]. Losses of meropenem are significant by convection and dose adaptations are necessary [3]. According to a population PK/PD model of meropenem developed in critically patients undergoing continuous RRT (CRRT), Isla et al. [4] recommended continuous infusion (CI) for treatment of pathogens with a MIC ≥ 4. In that study, meropenem was significantly eliminated by CRRT, necessitating steady-state doses of 1 g every 8 h to maintain concentrations active against more resistant organisms [4]. Because the stability of meropenem reconstituted in solution is influenced by storage temperature [5], it is advised to infuse 2 g meropenem for 8 h, 3 times daily to cover a 24 h period [3]. It stands to reason as in the Kothekar et al. paper that if drug dose adaptation was not done in CRRT patients and CI was not used in cases of pathogens with a MIC ≥ 4, some of the patients may have been underdosed, even with 1 g every 8 h. Again, in the Kothekar et al. paper it would be interesting to know the proportion of patients in the study who received CRRT, especially amongst the patients who failed to achieve adequate PK/PD.

Availability of data and materials

Not applicable.

Abbreviations

EI:

Extended infusions

fT:

Fraction of time

SOFA:

Sequential Organ Failure Assessment

RRT:

Renal replacement therapy

AKI:

Acute kidney injury

PK/PD:

Pharmacokinetics/pharmacodynamics

CRRT:

Continuous renal replacement therapy

CI:

Continuous infusion

MIC:

Minimum inhibitory concentration

References

  1. 1.

    Kothekar AT, Divatia JV, Myatra SN, et al. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria. Ann Intensive Care. 2020;10(1):4. https://doi.org/10.1186/s13613-019-0622-8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Peters E, Antonelli M, Wittebole X, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from the intensive care over nations audit. Crit Care. 2018;22(1):188. https://doi.org/10.1186/s13054-018-2112-z.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Honore PM, Jacobs R, De Waele E, Spapen HD. Applying pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy. Anaesthesiol Intensive Ther. 2017;49(5):412–8. https://doi.org/10.5603/AIT.a2017.0071.

    Article  Google Scholar 

  4. 4.

    Isla A, Rodríguez-Gascón A, Trocóniz IF, et al. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet. 2008;47(3):173–80. https://doi.org/10.2165/00003088-200847030-00003.

    CAS  Article  Google Scholar 

  5. 5.

    Jaruratanasirikul S, Sriwiriyajan S. Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health. 2003;34(3):627–9.

    Google Scholar 

Download references

Acknowledgements

We would like to thank Dr Melissa Jackson for critical review of the manuscript.

Funding

None.

Author information

Affiliations

Authors

Contributions

PMH, SR, DDB designed the paper. All authors participated in drafting and reviewing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Patrick M. Honore.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare to have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Honore, P.M., Barret Gutierrez, L., Kugener, L. et al. 500 mg as bolus followed by an extended infusion of 1500 mg of meropenem every 8 h failed to achieve in one-third of the patients an optimal PK/PD against non-resistant strains of these organisms: is CRRT responsible for this situation?. Ann. Intensive Care 10, 163 (2020). https://doi.org/10.1186/s13613-020-00777-2

Download citation